Does Cannabis Legalization Endanger Children and Adolescents? The Cannabis Act (CanG) came into force on April 1, 2024. It regulates the "controlled supply of cannabis to adults for recreational purposes". In the USA, legalization has contributed to a decrease in the risk perception of the health hazards of consumption and an increase in risky consumption patterns, including among adolescents. The use of cannabis-related emergency and addiction treatment has risen sharply. Similar developments are now to be feared for Germany. For children and adolescents with cannabis-related disorders, a high standard of quality is maintained in the addiction departments of child and adolescent psychiatric and psychotherapeutic clinics with qualified withdrawal treatment and the subsequent treatment of comorbid mental disorders. However, the number of hospital beds is not sufficient to meet demand. This also applies to the medical rehabilitation measures for children and adolescents with the indications of cannabis abuse and addiction, which are too limited. There is a risk that children and young people will suffer in two ways as a result of the change in drug policy. Conclusion: The CanG sends the wrong signal for addiction prevention. Just a few months after the CanG came into force, the cannabis industry is already expanding. International evidence indicates that legalization endangers the health of the younger generation. Instead of a CanG, the better path for young people would have been to strengthen cannabis-related education and prevention in Germany.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.13109/prkk.2024.73.7.652 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A plain language summary of results from the TORCHLIGHT trial of toripalimab plus chemotherapy for metastatic or recurrent triple-negative breast cancer.
Future Oncol
December 2024
TopAlliance Biosciences, Rockville, MD, USA.
Does Cannabis Legalization Endanger Children and Adolescents? The Cannabis Act (CanG) came into force on April 1, 2024. It regulates the "controlled supply of cannabis to adults for recreational purposes". In the USA, legalization has contributed to a decrease in the risk perception of the health hazards of consumption and an increase in risky consumption patterns, including among adolescents.
View Article and Find Full Text PDFSavolitinib in patients in China with locally advanced or metastatic treatment-naive non-small-cell lung cancer harbouring MET exon 14 skipping mutations: results from a single-arm, multicohort, multicentre, open-label, phase 3b confirmatory study.
Lancet Respir Med
December 2024
Department of Medical Oncology, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. Electronic address:
Article Synopsis
- Savolitinib has been approved in China for treating advanced non-small-cell lung cancer (NSCLC) with specific genetic mutations, particularly in patients who haven't had prior treatments or can't undergo platinum-based chemotherapy.
- A phase 3b study evaluated the drug's safety and effectiveness in treatment-naive patients with these mutations across 48 hospitals in China, administering different dosages based on patient weight.
- Results showed a promising objective response rate of 62% based on independent assessments, with the majority of patients experiencing some treatment-related side effects, the most common being peripheral edema.
Befotertinib for patients with pretreated EGFR T790M mutated locally advanced or metastatic NSCLC: Final overall survival results from a phase 2 trial.
Lung Cancer
September 2024
Betta Pharmaceuticals Co., Ltd, Hangzhou, China.
Article Synopsis
- The study analyzed the effectiveness of befotertinib, a drug for treating non-small cell lung cancer with EGFR T790M mutation, showing positive outcomes in patients with brain metastases and a manageable safety profile.
- Two groups of patients received different doses of the drug, and after tracking their progress for nearly four years, the overall survival rates were reported as 23.9 months and 31.5 months for the lower and higher doses, respectively.
- The results suggest that befotertinib offers significant overall survival benefits compared to other third-generation treatments, with adverse effects mostly manageable and in line with previous findings for similar cancer types.
Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial.
Nat Med
January 2024
TopAlliance Biosciences, Rockville, MD, USA.
Article Synopsis
- The TORCHLIGHT trial tested the combination of the immune-checkpoint inhibitor toripalimab and nab-paclitaxel (nab-P) against a placebo with nab-P in patients with advanced triple-negative breast cancer (TNBC).
- Results showed that the toripalimab group had a significantly longer progression-free survival (PFS) of 8.4 months compared to 5.6 months for the placebo group, particularly in PD-L1-positive patients.
- The overall survival was also better for the toripalimab group (32.8 months vs. 19.5 months), and the safety profile was similar between groups, suggesting that toripalimab is a promising treatment for this cancer type.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!